Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

doi:10.1038/s41423-021-00648-1

. 2021 Apr;18(4):1061-1063.

doi: 10.1038/s41423-021-00648-1. Epub 2021 Feb 25.

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Jie Hu^#¹, Pai Peng^#¹, Kai Wang^#¹, Liang Fang², Fei-Yang Luo³, Ai-Shun Jin³, Bei-Zhong Liu⁴, Ni Tang⁵, Ai-Long Huang⁶

Affiliations

¹ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
² Yong-Chuan Hospital, Chongqing Medical University, Chongqing, China.
³ Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
⁴ Yong-Chuan Hospital, Chongqing Medical University, Chongqing, China. liubeizhong@cqmu.edu.cn.
⁵ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. nitang@cqmu.edu.cn.
⁶ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. ahuang@cqmu.edu.cn.

^# Contributed equally.

PMID: 33633321
PMCID: PMC7905196
DOI: 10.1038/s41423-021-00648-1

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Jie Hu et al. Cell Mol Immunol. 2021 Apr.

. 2021 Apr;18(4):1061-1063.

doi: 10.1038/s41423-021-00648-1. Epub 2021 Feb 25.

Authors

Jie Hu^#¹, Pai Peng^#¹, Kai Wang^#¹, Liang Fang², Fei-Yang Luo³, Ai-Shun Jin³, Bei-Zhong Liu⁴, Ni Tang⁵, Ai-Long Huang⁶

Affiliations

¹ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
² Yong-Chuan Hospital, Chongqing Medical University, Chongqing, China.
³ Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
⁴ Yong-Chuan Hospital, Chongqing Medical University, Chongqing, China. liubeizhong@cqmu.edu.cn.
⁵ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. nitang@cqmu.edu.cn.
⁶ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. ahuang@cqmu.edu.cn.

^# Contributed equally.

PMID: 33633321
PMCID: PMC7905196
DOI: 10.1038/s41423-021-00648-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1. Neutralizing activities of convalescent sera and monoclonal antibodies against SARS-CoV-2 variants.**
a Infectivity of WT and variant pseudoviruses assessed in 293T-ACE2 and A549-ACE2 cells. Cells were inoculated with equivalent doses of each pseudotyped virus. WT, wild-type Spike (GenBank: QHD43416) pseudotyped virus; Variant 1, N501Y.V1 mutant Spike pseudotyped virus (containing the H60/V70 and Y144 deletions and N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations); Variant 2, N501Y.V2 mutant Spike pseudotyped virus (containing the K417N, E484K, N501Y, and D614G mutations). Neutralization of WT and variant pseudoviruses by convalescent sera. Pseudovirus-based neutralization assays were performed to detect neutralizing antibody (NAb) titers against SARS-CoV-2. The thresholds of detection were 1:40 of the ID₅₀. Twenty sera (indicated by circles) were drawn 5 to 33 days post symptom onset (b); 20 sera (indicated by triangles) were drawn ~8 months post symptom onset (c). The half-maximal inhibitory concentrations (IC₅₀) for tested monoclonal antibodies (mAbs) against pseudoviruses (d) and representative neutralization curves (e)

See this image and copyright information in PMC

Cited by

Sustained seropositivity up to 20.5 months after COVID-19.
Dobaño C, Ramírez-Morros A, Alonso S, Rubio R, Ruiz-Olalla G, Vidal-Alaball J, Macià D, Catalina QM, Vidal M, Casanovas AF, Prados de la Torre E, Barrios D, Jiménez A, Zanoncello J, Melero NR, Carolis C, Izquierdo L, Aguilar R, Moncunill G, Ruiz-Comellas A. Dobaño C, et al. BMC Med. 2022 Oct 13;20(1):379. doi: 10.1186/s12916-022-02570-3. BMC Med. 2022. PMID: 36224590 Free PMC article.
Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses.
Islam MM, Koirala D. Islam MM, et al. Anal Chim Acta. 2022 May 29;1209:339338. doi: 10.1016/j.aca.2021.339338. Epub 2021 Dec 1. Anal Chim Acta. 2022. PMID: 35569864 Free PMC article. Review.
Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection.
Comba IY, Riestra Guiance I, Corsini Campioli C, Challener D, Sampathkumar P, Orenstein R, Gordon J, Bosch W, O'Horo JC. Comba IY, et al. Mayo Clin Proc Innov Qual Outcomes. 2022 Aug;6(4):361-372. doi: 10.1016/j.mayocpiqo.2022.05.004. Epub 2022 May 30. Mayo Clin Proc Innov Qual Outcomes. 2022. PMID: 35665315 Free PMC article.
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021.
Alkhatib M, Svicher V, Salpini R, Ambrosio FA, Bellocchi MC, Carioti L, Piermatteo L, Scutari R, Costa G, Artese A, Alcaro S, Shafer R, Ceccherini-Silberstein F. Alkhatib M, et al. Microbiol Spectr. 2021 Dec 22;9(3):e0109621. doi: 10.1128/Spectrum.01096-21. Epub 2021 Nov 17. Microbiol Spectr. 2021. PMID: 34787497 Free PMC article.
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y, Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H, Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L, Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. Makdasi E, et al. Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21. Cell Rep. 2021. PMID: 34464610 Free PMC article.

See all "Cited by" articles

References

1. Ibarrondo FJ, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 2020;383:1085–1087. doi: 10.1056/NEJMc2025179. - DOI - PMC - PubMed
1. Peng, P. et al. Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cell. Mol. Immunol. 2021. 10.1038/s41423-020-00605-4. - PMC - PubMed
1. Zhang, J. et al. COVID-19 reinfection in the presence of neutralizing antibodies. Natl Sci. Rev. 2021. 10.1093/nsr/nwab006. - PMC - PubMed
1. Han, X. et al. A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD. bioRxiv 2020. 10.1101/2020.08.19.253369.
1. Hu J, et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 2020;7:551–557. doi: 10.1016/j.gendis.2020.07.006. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Ibarrondo FJ, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 2020;383:1085–1087. doi: 10.1056/NEJMc2025179. - DOI - PMC - PubMed

[2] Ibarrondo FJ, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 2020;383:1085–1087. doi: 10.1056/NEJMc2025179. - DOI - PMC - PubMed

[3] Peng, P. et al. Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cell. Mol. Immunol. 2021. 10.1038/s41423-020-00605-4. - PMC - PubMed

[4] Peng, P. et al. Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cell. Mol. Immunol. 2021. 10.1038/s41423-020-00605-4. - PMC - PubMed

[5] Zhang, J. et al. COVID-19 reinfection in the presence of neutralizing antibodies. Natl Sci. Rev. 2021. 10.1093/nsr/nwab006. - PMC - PubMed

[6] Zhang, J. et al. COVID-19 reinfection in the presence of neutralizing antibodies. Natl Sci. Rev. 2021. 10.1093/nsr/nwab006. - PMC - PubMed

[7] Han, X. et al. A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD. bioRxiv 2020. 10.1101/2020.08.19.253369.

[8] Han, X. et al. A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD. bioRxiv 2020. 10.1101/2020.08.19.253369.

[9] Hu J, et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 2020;7:551–557. doi: 10.1016/j.gendis.2020.07.006. - DOI - PMC - PubMed

[10] Hu J, et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 2020;7:551–557. doi: 10.1016/j.gendis.2020.07.006. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Affiliations

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous